Navigation Links
Experimental Drug Might Help Fight Alzheimer's After All
Date:7/20/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, July 20 (HealthDay News)-- An experimental drug for treating Alzheimer's disease that previously showed troubling side effects may actually be safe in the long run, researchers report.

The keys to the safety of the drug, bapineuzumab, may be lowering the dose and not giving it to patients with ApoE4, a gene mutation linked to Alzheimer's, according to two studies scheduled for presentation Wednesday at the Alzheimer's Association International Conference on Alzheimer's Disease in Paris.

"The data from the open-label trial are encouraging. Patients were able to tolerate bapineuzumab for two to four additional years without the emergence of any new safety concerns," said Dr. Stephen Salloway, author of one of the studies. "This is important because we are conceptualizing this drug as a long-term treatment for Alzheimer's disease."

Encouraging does not translate into certainty, however, another expert pointed out.

"I think it is too early to tell from the data from this small Phase 2 safety trial," said Ian Murray, an assistant professor of neuroscience and experimental therapeutics at Texas A&M Health Science Center College of Medicine in College Station. "We will have to wait for larger trials to comment on this as a potential therapy."

The studies were funded by Pfizer Inc. and Janssen Alzheimer Immunotherapy.

Although bapineuzumab has shown promise in certain Alzheimer's patients, other research found that patients taking a higher dose of the drug had an increased risk of brain inflammation from water retention. This resulted in headache, memory loss, hallucinations, reduced coordination or other symptoms. But no problems were seen with lower doses.

Bapineuzumab is a humanized monoclonal antibody, which binds to and might be able to eliminate beta amyloid peptide in the brains of people with Alzheimer's. Most experts believe that the build up of beta amyloid proteins, which accumulate as plaque, is responsible for Alzheimer's.

Salloway's study looked at the drug's safety in 194 Alzheimer's patients, most of whom had mild- to-moderate Alzheimer's and participated in a long-term (78 weeks or longer) study. Some of the participants were followed for four years or more.

Ninety-one percent of participants had side effects, about a quarter of which were attributable to bapineuzumab. Of these, 85 percent were mild or moderate.

The overall rate of vasogenic edema (water on the brain) was 9.3 percent, a number that decreased over time, said Salloway, a professor of neurology and psychiatry at Alpert Medical School of Brown University and director of the Butler Hospital Memory and Aging Program in Providence, R.I. The edema was symptomless in most cases, he said.

The other study, which involved looking at more than 2,000 MRI scans from 262 patients, found 36 cases of amyloid-related imaging abnormalities (ARIA) may have been linked to the bapineuzumab.

These imaging abnormalities may indicate inflammation of the brain caused by water retention.

But only 8 of those 36 cases involved symptoms, and they were more likely to be found in patients with APOE-e4 who were taking higher doses of the drug. The likelihood of these effects diminished with additional infusions of lower-dose bapineuzumab.

"There is a growing sense that VE [vasogenic edema] or ARIA [amyloid-related imaging abnormalities] is a manageable side effect and may actually be a sign that the drug is clearing amyloid from the brain and the blood vessels," said Salloway. "Treatment will require ongoing monitoring with MRI."

The researchers, who said monitoring of bapineuzumab will continue, are now awaiting the results of a larger Phase III trial on the drug.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

The Alzheimer's Association has more on this condition.

SOURCES: Stephen Salloway, M.D., professor, neurology and psychiatry, Alpert Medical School of Brown University, and director, Butler Hospital Memory and Aging Program, Providence, R.I.; Ian Murray, Ph.D., assistant professor, neuroscience and experimental therapeutics, Texas A&M Health Science Center College of Medicine, College Station; July 20, 2011, presentation, Alzheimer's Association International Conference on Alzheimer's Disease, Paris


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
2. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
3. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
4. Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
5. Experimental treatment offers relief from painful prostate condition
6. Christos Mantzoros honored by Federation of the American Societies for Experimental Biology
7. Experimental Test May Warn of Premature Births
8. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
9. Experimental Weight-Loss Drug Seems to Work: Study
10. Experimental drug achieves unprecedented weight loss
11. Science at a glance: Symposia, research and special events at Experimental Biology 2011
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Might Help Fight Alzheimer's After All
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... report to their offering. ... failure, it replaces the function of kidneys by removing the ... the treatment helps to keep the patient body,s electrolytes such ... Increasing number of ESRD patients & substantial healthcare expenditure on ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: